The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials
Abstract
CONTEXT: Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies. OBJECTIVE: To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of anti-TNF therapy. DATA SOURCES: A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews of the manufacturers of the 2 licensed anti-TNF antibodies. STUDY SELECTION: We included randomized, placebo-controlled trials of the 2 licensed anti-TNF antibodies (infliximab and adalimumab) used for 12 weeks or more in patients with rheumatoid arthritis. Nine trials met our inclusion criteria, including 3493 patients who received anti-TNF antibody treatment and 1512 patients who received placebo. DATA EXTRACTION: Data on study characteristics to assess study quality and intention-to-treat data for serious infections and malignancies were abstracted. Published information from the trials was supplemented by direct contact between principal investigators and industry sponsors. DATA SYNTHESIS: We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF-treated patients vs placebo patients. We estimated effects for high and low doses separately. The pooled odds ratio for malignancy was 3.3 (95% confidence interval [CI], 1.2-9.1) and for serious infection was 2.0 (95% CI, 1.3-3.1). Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies. For patients treated with anti-TNF antibodies in the included trials, the number needed to harm was 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months. For serious infections, the number needed to harm was 59 (95% CI, 39-125) within a treatment period of 3 to 12 months. CONCLUSIONS: There is evidence of an increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy. The formal meta-analysis with pooled sparse adverse events data from randomized controlled trials serves as a tool to assess harmful drug effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis
Widdifield, J., Bernatsky, S., Paterson, J. M., Gunraj, N., Thorne, J. C., Pope, J., Cividino, A., & Bombardier, C. (2013) · Arthritis Care & Research · doi:10.1002/acr.21812 · Cited by 219
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Yun, H., Xie, F., Delzell, E., Levitan, E. B., Chen, L., Lewis, J. D., Saag, K. G., Beukelman, T., Winthrop, K. L., Baddley, J. W., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39399 · Cited by 152
Psoralen and Ultraviolet A Light Therapy for Psoriasis
Stern, R. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmct072317 · Cited by 149
Rituximab-treated patients have a poor response to influenza vaccination
Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9813-x · Cited by 126
Gilotra, N. A., GRIFFIN, J. M., PAVLOVIC, N., HOUSTON, B. A., CHASLER, J., GOETZ, C., CHRISPIN, J., SHARP, M., KASPER, E. K., CHEN, E. S., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.06.016 · Cited by 94
Fischer, L., Gerstel, P. F., Poncet, A., Siegrist, C.-A., Laffitte, E., Gabay, C., Seebach, J. D., & Ribi, C. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0663-9 · Cited by 73
“Prednisone has been associated with pneumonia [4, 5], and cyclophosphamide, azathioprine and newer biologic agents such as tumor necrosis factor (TNF)-α blockers have been shown to confer an increased risk of infection [6–9].”
BackgroundZhang, N., Wang, Z., & Zhao, Y. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.03.002 · Cited by 72
Løbner, M., Walsted, A., Larsen, R., Bendtzen, K., & Nielsen, C. H. (2008) · Journal of Medicinal Food · doi:10.1089/jmf.2007.564 · Cited by 66
Primer: strengths and weaknesses of meta-analysis
Finckh, A., & Tramèr, M. R. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0732 · Cited by 62
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
Gao, X., Kang, X., Lu, H., Xue, E., Chen, R., Pan, J., & Ma, J. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12696 · Cited by 26
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-05-17
- Volume
- 295
- Issue
- 19
- Pages
- 2275
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2131882149
- Cited by
- 2,468
- References
- 3
- FWCI
- 134.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
